169 related articles for article (PubMed ID: 34997684)
21. WHO working group meeting to develop WHO Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines.
Lei D; Griffiths E; Martin J
Vaccine; 2020 Jul; 38(32):4917-4923. PubMed ID: 32418797
[TBL] [Abstract][Full Text] [Related]
22. Chimeric enterovirus 71 virus-like particle displaying conserved coxsackievirus A16 epitopes elicits potent immune responses and protects mice against lethal EV71 and CA16 infection.
Luo J; Huo C; Qin H; Hu J; Lei L; Pan Z
Vaccine; 2021 Jul; 39(30):4135-4143. PubMed ID: 34116877
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice.
Sun S; Gao F; Mao Q; Shao J; Jiang L; Liu D; Wang Y; Yao X; Wu X; Sun B; Zhao D; Ma Y; Lu J; Kong W; Jiang C; Liang Z
Hum Vaccin Immunother; 2015; 11(10):2406-13. PubMed ID: 26036916
[TBL] [Abstract][Full Text] [Related]
24. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses.
Cai Y; Ku Z; Liu Q; Leng Q; Huang Z
Vaccine; 2014 May; 32(21):2406-12. PubMed ID: 24657161
[TBL] [Abstract][Full Text] [Related]
25. Hand-Foot-and-Mouth Disease-Associated Enterovirus and the Development of Multivalent HFMD Vaccines.
Zhang X; Zhang Y; Li H; Liu L
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613612
[TBL] [Abstract][Full Text] [Related]
26. A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus.
Wu Y; Zhu R; Xu L; Li Y; Li S; Yu H; Li S; Zhu H; Cheng T; Xia N
Vaccine; 2017 May; 35(20):2728-2735. PubMed ID: 28408118
[TBL] [Abstract][Full Text] [Related]
27. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD).
Mao QY; Wang Y; Bian L; Xu M; Liang Z
Expert Rev Vaccines; 2016 May; 15(5):599-606. PubMed ID: 26732723
[TBL] [Abstract][Full Text] [Related]
28. Structure, Immunogenicity, and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid.
Wang X; Ku Z; Zhang X; Ye X; Chen J; Liu Q; Zhang W; Zhang C; Fu Z; Jin X; Cong Y; Huang Z
J Virol; 2018 Jan; 92(1):. PubMed ID: 29070691
[TBL] [Abstract][Full Text] [Related]
29. Similar protective immunity induced by an inactivated enterovirus 71 (EV71) vaccine in neonatal rhesus macaques and children.
Zhang Y; Wang L; Liao Y; Liu L; Ma K; Yang E; Wang J; Che Y; Jiang L; Pu J; Guo L; Feng M; Liang Y; Cui W; Yang H; Li Q
Vaccine; 2015 Nov; 33(46):6290-7. PubMed ID: 26419198
[TBL] [Abstract][Full Text] [Related]
30. The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.
Mao Q; Wang Y; Shao J; Ying Z; Gao F; Yao X; Li C; Ye Q; Xu M; Li R; Zhu F; Liang Z
Hum Vaccin Immunother; 2015; 11(11):2723-33. PubMed ID: 25715318
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of an inactivated bivalent vaccine for enterovirus 71 and coxsackievirus A16 in mice immunized intradermally.
Fan S; Liao Y; Jiang G; Wang L; Zhao H; Yu L; Xu X; Li D; Zhang Y; Li Q
Vaccine; 2021 Jan; 39(3):596-604. PubMed ID: 33342637
[TBL] [Abstract][Full Text] [Related]
32. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease.
Fang CY; Liu CC
Expert Rev Vaccines; 2018 Sep; 17(9):819-831. PubMed ID: 30095317
[TBL] [Abstract][Full Text] [Related]
33. Enhanced neutralizing antibody response induced by inactivated enterovirus 71 in cynomolgus monkeys.
In HJ; Lim H; Lee JA; Lee SR; Jin YB; Jeong KJ; Hyeon JY; Yoo JS; Lee JW; Choi YK; Lee SW
PLoS One; 2018; 13(10):e0202552. PubMed ID: 30278051
[TBL] [Abstract][Full Text] [Related]
34. Update on the development of enterovirus 71 vaccines.
Kung YA; Hung CT; Liu YC; Shih SR
Expert Opin Biol Ther; 2014 Oct; 14(10):1455-64. PubMed ID: 24989170
[TBL] [Abstract][Full Text] [Related]
35. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice.
Zhang C; Ku Z; Liu Q; Wang X; Chen T; Ye X; Li D; Jin X; Huang Z
Vaccine; 2015 May; 33(20):2335-41. PubMed ID: 25820068
[TBL] [Abstract][Full Text] [Related]
36. EV71 vaccines: a first step towards multivalent hand, foot and mouth disease vaccines.
Klein MH
Expert Rev Vaccines; 2015 Mar; 14(3):337-40. PubMed ID: 25536888
[TBL] [Abstract][Full Text] [Related]
37. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice.
Li HY; Han JF; Qin CF; Chen R
Vaccine; 2013 Jul; 31(32):3281-7. PubMed ID: 23726823
[TBL] [Abstract][Full Text] [Related]
38. Protective effect of enterovirus‑71 (EV71) virus‑like particle vaccine against lethal EV71 infection in a neonatal mouse model.
Cao L; Mao F; Pang Z; Yi Y; Qiu F; Tian R; Meng Q; Jia Z; Bi S
Mol Med Rep; 2015 Aug; 12(2):2473-80. PubMed ID: 25936344
[TBL] [Abstract][Full Text] [Related]
39. Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate.
Tsai YH; Huang SW; Hsieh WS; Cheng CK; Chang CF; Wang YF; Wang JR
J Virol; 2019 Jul; 93(13):. PubMed ID: 30996087
[TBL] [Abstract][Full Text] [Related]
40. Hand, foot and mouth disease and herpangina caused by enterovirus A71 infections: a review of enterovirus A71 molecular epidemiology, pathogenesis, and current vaccine development.
Chang YK; Chen KH; Chen KT
Rev Inst Med Trop Sao Paulo; 2018 Nov; 60():e70. PubMed ID: 30427405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
